References
- No authors listed. Cost of living: why do some drugs cost so much? Economist 366(8313), 60 (2003).
- Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs20(5), 241–251 (2001).
- Lichtenberg FR. The effect of pharmaceutical utilization and innovation on hospitalization and mortality NBER Working Paper 5418, January 1996.
- Patented Medicine Prices Review Board. Annual report 2000. Ottawa, Canada (2001).
- No authors listed. Drugs in 2001: a number of ruses unveiled. Presaire Int. 11, 58–60 (2002).
- Yasuda SU, Woosley RL. The clinical value of FDA class C drugs approved from 1981 to 1988. Clin. Phalmacol. Ther. 52, 577–582 (1992).
- No authors listed. Ursodeoxycholic acid. Primary biliary cirrhosis: dashed hopes. Presaire Int. 11, 67–69 (2002).
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor vs calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JA/V/A 288, 2981–2997 (2002).
- Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med.j 321, 1371–1376 (2000).
- Lichtenberg FR. New drugs and lower costs. Am. J. Health Sys. Pharmacy59, 1894–1895 (2002).
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized trial. JAIVIA 288, 321–333 (2002).
- Lichtenberg FR. The health and economic benefits of new drugs. Fraser Forum February, 10–12 (2003).
Websites
- PhRIVIA www.pharma.org. (Accessed May 11, 2003)
- Lichtenberg E Do more (and better) medicines keep people out of hospitals? Pfizer Forum, 1992. www.pfizerforum.com/english/ lichtenberg.shtml (Accessed March 3, 2003).
- Pharmaceutical companies made 32 new treatments available to patients in 2001 and invested an estimated US$30.3 billion in research and development. www.phrma.org/mediaroom/press/releases/ 25.01.2002.329.cfm (Accessed March 3, 2003).
- COX-2 inhibitors update: do journal publications tell the full story? Therapeutics Letter 43, Nov/Dec/Jan (2001–2002). www.thubc.ca/pages/letter.html (Accessed March 3, 2003).
- National Institute for Health Care Management Research and Educational Foundation, Changing patterns of pharmaceutical innovation. NIHCM, Washington DC, May (2002) . www.nihcm.org (Accessed August 5, 2002).